key: cord-1022489-j24za76g authors: Berardis, S.; Verroken, A.; Vetillart, A.; Struyf, C.; Gilbert, M.; Gruson, D.; Gohy, S. title: SARS-CoV-2 seroprevalence in a belgian cohort of patients with cystic fibrosis date: 2020-08-11 journal: J Cyst Fibros DOI: 10.1016/j.jcf.2020.08.005 sha: 22340889f8c39415f88de6919addf04eecfa41d5 doc_id: 1022489 cord_uid: j24za76g BACKGROUND: In Belgium, COVID-19 epidemy began on February 4, 2020 with a peak on April 10, 2020. Patients with cystic fibrosis (CF) followed in the Cliniques universitaires Saint-Luc were rapidly isolated before the government lockdown. METHODS: After the peak of the epidemy, we measured anti-SARS-CoV-2 IgM and IgG antibodies in 149 patients and collected clinical data. RESULTS: Only 3 asymptomatic patients presented IgG against the virus. In one patient hospitalized for COVID-19 (positive molecular testing), we did not detect any anti-SARS-CoV-2 antibodies, as in thirty-five other symptomatic patients considered as possible cases. CONCLUSIONS: Even if respiratory symptoms linked to CF are frequent and compatible with COVID-19, anti-SARS-CoV-2 IgG antibodies were detected only in 3 asymptomatic patients. This reassuring study concerning the risk of COVID-19 in patients with CF illustrates the difficulty to distinguish COVID-19 symptoms from respiratory exacerbations and the need of generalized molecular testing to make a precise diagnosis. In Belgium, COVID-19 epidemy began on February 4, 2020 with a peak on April 10, 2020. Patients with cystic fibrosis (CF) followed in the Cliniques universitaires Saint-Luc were rapidly isolated before the government lockdown. After the peak of the epidemy, we measured anti-SARS-CoV-2 IgM and IgG antibodies in 149 patients and collected clinical data. Only 3 asymptomatic patients presented IgG against the virus. In one patient hospitalized for COVID-19 (positive molecular testing), we did not detect any anti-SARS-CoV-2 antibodies, as in thirty-five other symptomatic patients considered as possible cases. Even if respiratory symptoms linked to CF are frequent and compatible with COVID-19, anti-SARS-CoV-2 IgG antibodies were detected only in 3 asymptomatic patients. This reassuring study concerning the risk of COVID-19 in patients with CF illustrates the difficulty to distinguish COVID-19 symptoms from respiratory exacerbations and the need of generalized molecular testing to make a precise diagnosis. The coronavirus disease 2019 (COVID-19) is a new emerging infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The main risk factors associated with a worse outcome include age and comorbidities such as hypertension, diabetes mellitus or chronic lung disease (1) . Cystic fibrosis (CF) is a multisystemic disorder, responsible for a chronic lung disease. Obstruction of the airways by viscous secretions and the consecutive inflammation induce progressive destruction of the lungs. Several comorbidities are described in CF, including diabetes mellitus and liver disease (2) . Information is lacking on the prevalence and on the clinical impact of COVID-19 among CF patients. In a multinational report, 40 cases have been reported in 8 countries. In contrary with the H1N1 influenza pandemic in 2009-2010 where a significant morbidity was described among affected CF patients (3), the outcomes of COVID-19 in this population seem to be less severe than expected (4). To our knowledge, no data are available regarding the SARS-CoV-2 seroprevalence among CF patients. In this monocentric prospective study, we report SARS-CoV-2 seroprevalence of 149 CF patients. CF patients followed in the CF reference center of the Cliniques universitaires Saint-Luc, Brussels were recruited prospectively by receiving a letter containing an empty tube to test IgM and IgG against SARS-CoV-2. Between April 16, 2020 and May 19, 2020, sera were collected from 149 patients (first case in Belgium on February 4, 2020, peak of the epidemy on April 10, 2020, lockdown for CF patients since March 12, 2020). Blood sampling was performed either in the CF center or in another local center and brought the same day to the CF center through a drive-in system. Patients were contacted by phone to collect the presence and timing of symptoms. All patients respond to the classical definition of CF, defined by Farrell (5) . Clinical data are presented in the Table 1 . The local ethical committee stated that no informed consent was needed as the Helsinki declaration was respected, as it was considered as a regular monitoring in this sanitary crisis. Measurements of specific anti-SARS-CoV-2 IgM and IgG antibodies were performed with the From the 149 patients, 36 (24%) had compatible symptoms. During the lockdown, only hospitalized patients were tested because of the lack of material. One patient was hospitalized for a respiratory exacerbation and SARS-CoV-2 was detected by PCR. Two patients were hospitalized for other reasons and tested negative. PCR was also negative for two other patients hospitalized for respiratory exacerbations and for one suspected patient tested by his general practitioner. These data suggest that SARS-CoV-2 seroprevalence among CF patients is low (2.7%) and even lower than in the Belgian population in the same period (4.3 %) (9). These results may be partly explained by the early recommendation towards our CF patients to limit the faceto-face contacts, while the directive of social shielding was adopted a few days later by the Belgian government on March 18, 2020. Moreover, CF patients are familiar with protective measures (use of face masks and hand hygiene). The protective/curative role of azithromycin is still debated (10) . We reported that the presence of anti-SARS-CoV-2 antibodies in CF patients is not always correlated to the clinical presentation. The 3 patients with positive anti-SARS-CoV-2 IgG were asymptomatic. The detection of anti-SARS-CoV-2 IgG among asymptomatic patients has been described in a Chinese control group around 5% (11) . As anti-SARS-CoV-2 IgG assays have been reported to have a great specificity (11) 8 We report the first data on SARS-CoV-2 seroprevalence in a large cohort of CF patients. While possible cases were frequent, antibodies were detected only in a minority of patients, probably reflecting the low incidence of COVID-19 in this population. This study also illustrates the similarity of COVID-19 symptoms and respiratory exacerbations and the need of generalized molecular testing to make a precise diagnosis. The authors have declared that no conflict of interest exists. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China Cystic fibrosis genetics: from molecular understanding to clinical application Influenza A(H1N1)pdm09 and Cystic Fibrosis Lung Disease: A Systematic Meta-Analysis A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation Analytical Performances of a Chemiluminescence Immunoassay for SARS-CoV-2 IgM/IgG and Antibody Kinetics Assessment of immune response to SARS-CoV-2 with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Antibody detection and dynamic characteristics in patients with COVID-19 The role of antibody testing for SARS-CoV-2: Is there one Convergent antibody response to SARS-CoV-2 in convalescent individuals Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 Re: Profile of specific antibodies to SARS-CoV-2 : The first report